# EDGAR Filing Document

**Accession Number:** 0001968554
**File Stem:** 0000899243-23-008745
**Filing Date:** 2023-3
**Character Count:** 10814
**Document Hash:** fa98ce89bdcf025a03b1235ec1dc0f12
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000899243-23-008745.hdr.sgml**: 20230316

**ACCESSION NUMBER**: 0000899243-23-008745

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230307

**FILED AS OF DATE**: 20230316

**DATE AS OF CHANGE**: 20230316

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Jordan Julie
- **CENTRAL INDEX KEY:** 0001968554

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38433
- **FILM NUMBER:** 23739658

**MAIL ADDRESS:**
- **STREET 1:** C/O HOMOLOGY MEDICINES, INC.
- **STREET 2:** ONE PATRIOTS PARK
- **CITY:** BEDFORD
- **STATE:** MA
- **ZIP:** 01730
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Homology Medicines, Inc.
- **CENTRAL INDEX KEY:** 0001661998
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 473468154
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** ONE PATRIOTS PARK
- **CITY:** BEDFORD
- **STATE:** MA
- **ZIP:** 01730
- **BUSINESS PHONE:** 781-301-7277

**MAIL ADDRESS:**
- **STREET 1:** ONE PATRIOTS PARK
- **CITY:** BEDFORD
- **STATE:** MA
- **ZIP:** 01730

## Ex-24

```
<PRE>
                                                                      EXHIBIT 24

                               POWER OF ATTORNEY

With respect to holdings of and transactions in securities issued by Homology
Medicines, Inc. (the "Company"), the undersigned hereby constitutes and appoints
the individuals named on Schedule A attached hereto and as may be amended from
time to time, or any of them signing singly, with full power of substitution and
resubstitution, to act as the undersigned's true and lawful attorney-in-fact to:

      1.  prepare, execute in the undersigned's name and on the undersigned's
          behalf, and submit to the United States Securities and Exchange
          Commission (the "SEC") a Form ID, including amendments thereto, and
          any other documents necessary or appropriate to obtain and/or
          regenerate codes and passwords enabling the undersigned to make
          electronic filings with the SEC of reports required by Section 16(a)
          of the Securities Exchange Act of 1934, as amended, or any rule or
          regulation of the SEC;

      2.  execute for and on behalf of the undersigned, Forms 3, 4, and 5 in
          accordance with Section 16 of the Securities Exchange Act of 1934, as
          amended, and the rules thereunder;

      3.  do and perform any and all acts for and on behalf of the undersigned
          which may be necessary or desirable to complete and execute any such
          Form 3, 4, or 5, complete and execute any amendment or amendments
          thereto, and timely file such form with the SEC and any stock exchange
          or similar authority; and

      4.  take any other action of any type whatsoever in connection with the
          foregoing which, in the opinion of such attorney-in-fact, may be of
          benefit to, in the best interest of, or legally required by, the
          undersigned, it being understood that the documents executed by such
          attorney-in-fact on behalf of the undersigned pursuant to this Power
          of Attorney shall be in such form and shall contain such terms and
          conditions as such attorney-in-fact may approve in such attorney-in-
          facts discretion.

The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution and
resubstitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorneys-in-fact substitute or substitutes, shall
lawfully do or cause to be done by virtue of this Power of Attorney and the
rights and powers herein granted.

The undersigned acknowledges that the foregoing attorneys-in-fact, in serving
in such capacity at the request of the undersigned, are not assuming, nor is any
Company assuming, any of the undersigned's responsibilities to comply with
Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 7th day of March, 2023.

                                        By:   /s/ Julie Jordan
                                              -----------------------
                                        Name:  Julie Jordan

                                   Schedule A

Individuals Appointed as Attorney-in-Fact with Full Power of Substitution and
Resubstitution

    1.  W. Bradford Smith
    2.  Paul Alloway
    3.  Albert Seymour

</PRE>
```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Jordan Julie<br><sub>(Last) (First) (Middle)</sub><br>C/O HOMOLOGY MEDICINES, INC.<br>ONE PATRIOTS PARK<br><sub>(Street)</sub><br>BEDFORD, MA 01730<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Homology Medicines, Inc. [ FIXX ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2023-03-07 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Chief Medical Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 2519 | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Employee Stock Option (Right to Buy) | <sup>(1)</sup> | 2031-06-02 | Common Stock | 65000 | $6.53 | D |  |
| Employee Stock Option (Right to Buy) | <sup>(2)</sup> | 2032-02-24 | Common Stock | 56000 | $2.71 | D |  |
| Employee Stock Option (Right to Buy) | <sup>(3)</sup> | 2032-03-02 | Common Stock | 9000 | $3.59 | D |  |
| Employee Stock Option (Right to Buy) | <sup>(4)</sup> | 2033-02-23 | Common Stock | 143000 | $1.60 | D |  |
| Restricted Stock Units | <sup>(5)</sup> | <sup>(6)</sup> | Common Stock | 350 | <sup>(6)</sup> | D |  |
| Restricted Stock Units | <sup>(7)</sup> | <sup>(6)</sup> | Common Stock | 5360 | <sup>(6)</sup> | D |  |
| Restricted Stock Units | <sup>(8)</sup> | <sup>(6)</sup> | Common Stock | 1340 | <sup>(6)</sup> | D |  |
| Restricted Stock Units | <sup>(9)</sup> | <sup>(6)</sup> | Common Stock | 24000 | <sup>(6)</sup> | D |  |

---

### Footnotes:

(1) The option vests or has vested as to 25% of the underlying shares on May 3, 2022 and in 36 substantially equal monthly installments upon the Reporting Person's completion of each full month of service thereafter so that such option will become fully vested on May 3, 2025.

(2) The option vests in 48 substantially equal monthly installments upon the Reporting Person's completion of each full month of service following January 1, 2022 so that such option will become fully vested on January 1, 2026.

(3) The option vests in 48 substantially equal monthly installments upon the Reporting Person's completion of each full month of service following January 1, 2022 so that such option will become fully vested on January 1, 2026.

(4) The option vests in 48 substantially equal monthly installments upon the Reporting Person's completion of each full month of service following January 1, 2023 so that such option will become fully vested on January 1, 2027.

(5) The restricted stock units will vest and settle in full on August 2, 2023.

(6) Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units have no expiration date.

(7) The restricted stock units will vest and settle as to one half of the restricted stock units on each of January 1, 2024 and January 1, 2025.

(8) The restricted stock units will vest and settle as to one half of the restricted stock units on each of January 1, 2024 and January 1, 2025.

(9) The restricted stock units will vest and settle as to one third of the restricted stock units on each of the first three anniversaries of January 1, 2023 so that such RSUs will become fully vested on January 1, 2026.

**Remarks:**
Exhibit 24 - Power of Attorney.

**Signature:** /s/ Paul Alloway, Attorney-in-Fact for Julie Jordan  
**Date:** 2023-03-16

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**